Intravitreal Adalimumab in Active Noninfectious Uveitis: A Pilot Study

Abstract Purpose: To evaluate the short-term efficacy of intravitreal adalimumab (IVA) for the treatment of eyes with active noninfectious uveitis. Methods: Consecutive eyes with active noninfectious uveitis were injected with IVA at 0, 2, then every 4 weeks for total of 26 weeks. Results: Six out of 7 patients (12 of 13 eyes) completed 26 weeks of treatment. One patient (1 eye) failed treatment. Seven out of 12 eyes had improvement of ≥2 ETDRS lines. Three out of three eyes had resolution of anterior chamber cells. And 9 of 10 eyes with vitreous haze had zero haze at 26 weeks. Five out of 8 eyes with macular edema had complete resolution. Median fluorescein angiography score improved from 14 to 4 on last follow-up. Conclusions: IVA was effective in controlling the inflammation, decreasing the macular edema, and improving the best corrected visual acuity in the majority of eyes in this series.

[1]  A. Heiligenhaus,et al.  A three-centre experience with adalimumab for the treatment of non-infectious uveitis , 2012, British Journal of Ophthalmology.

[2]  J. F. Arevalo,et al.  Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. , 2012, Ophthalmology.

[3]  J. Vander.  Dexamethasone Intravitreal Implant for Noninfectious Intermediate or Posterior Uveitis , 2012 .

[4]  Lihteh Wu,et al.  INTRAVITREAL TUMOR NECROSIS FACTOR INHIBITORS IN THE TREATMENT OF REFRACTORY DIABETIC MACULAR EDEMA: A Pilot Study From the Pan-American Collaborative Retina Study Group , 2011, Retina.

[5]  S. Androudi,et al.  Intravitreal adalimumab for refractory uveitis-related macular edema. , 2010, Ophthalmology.

[6]  J. Kempen,et al.  Cyclophosphamide for ocular inflammatory diseases. , 2010, Ophthalmology.

[7]  M. Tsilimbaris,et al.  Evaluation of potential retinal toxicity of adalimumab (Humira) , 2009, Graefe's Archive for Clinical and Experimental Ophthalmology.

[8]  M. Khairallah,et al.  Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis) , 2010, International Ophthalmology.

[9]  J. Callejas-Rubio,et al.  Adalimumab therapy for refractory uveitis: a pilot study. , 2008, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[10]  D. Jabs,et al.  Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. , 2008, Ophthalmology.

[11]  R. Caspi.  Autoimmunity in the immune privileged eye: pathogenic and regulatory T cells , 2008, Immunologic research.

[12]  P. Murray,et al.  Behçet's disease: Ocular effects and treatment , 2008, Progress in Retinal and Eye Research.

[13]  G. Peyman,et al.  Ocular toxicity of intravitreous adalimumab (Humira) in the rabbit , 2008, Graefe's Archive for Clinical and Experimental Ophthalmology.

[14]  A. Dick,et al.  Biologics in the treatment of uveitis , 2007, Current opinion in ophthalmology.

[15]  L. Sobrin,et al.  Infliximab therapy for the treatment of refractory ocular inflammatory disease. , 2007, Archives of ophthalmology.

[16]  M. Mochizuki,et al.  The Role of Soluble TNF Receptors for TNF-α in Uveitis , 2007 .

[17]  M. Mochizuki,et al.  The role of soluble TNF receptors for TNF-alpha in uveitis. , 2007, Investigative ophthalmology & visual science.

[18]  Justine R. Smith,et al.  Biologic therapies for inflammatory eye disease , 2006, Clinical & experimental ophthalmology.

[19]  Douglas A Jabs,et al.  Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. , 2005, American journal of ophthalmology.

[20]  M. Inanç,et al.  Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. , 2005, Arthritis and rheumatism.

[21]  P. Murray,et al.  Anti-TNF-α therapy for uveitis: Behçet and beyond , 2005, Eye.

[22]  Andrew D. Dick,et al.  The standardization of uveitis nomenclature (SUN) working group; standardization of uveitis nomenclature for reporting clinical data: Results of the first international workshop , 2005 .

[23]  P. Murray,et al.  Anti-TNF-alpha therapy for uveitis: Behçet and beyond. , 2005, Eye.

[24]  E. Collantes-Estévez,et al.  Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27 , 2004, Current medical research and opinion.

[25]  J. Forrester,et al.  Neutralizing tumor necrosis factor-alpha activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis. , 2003, Investigative ophthalmology & visual science.

[26]  E. Collantes Estévez,et al.  Aqueous Humor and Serum Tumor Necrosis Factor-α in Clinical Uveitis , 2001, Ophthalmic Research.

[27]  A Rothova,et al.  The possible impact of uveitis in blindness: a literature survey. , 1996, The British journal of ophthalmology.